AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have announced the first patient has been dosed in the TROPION-Lung17 Phase 3 trial, a landmark study that marks the first time an antibody-drug conjugate (ADC) is being evaluated using a prospective, AI-powered biomarker in lung cancer.
Sight Sciences (NASDAQ:SGHT), a leader in interventional eyecare technologies, released preliminary fourth-quarter 2025 results on Jan. 13, showing a return to growth driven by its interventional dry eye business.
Treace Medical Concepts (NASDAQ:TMCI) shares are under scrutiny after the bunion-correction specialist reported preliminary fourth-quarter revenue that reflected a nearly double-digit decline.
Armata Pharmaceuticals (NYSE:ARMP) is poised to become the first company to advance a bacteriophage candidate into a Phase 3 clinical trial, following a positive End-of-Phase 2 (EOP2) response from the U.S. Food and Drug Administration (FDA).
AerCap Holdings N.V. (NYSE:AER), the world’s largest aircraft lessor, has reached a significant agreement with Virgin Atlantic to finance six new Airbus A330-900 aircraft.
Cardinal Health (NYSE:CAH) raised its fiscal year 2026 earnings outlook Tuesday, citing rapid acceleration in its specialty pharmaceutical business and a successful navigating of federal drug pricing changes.
Lazard (NYSE:LAZ) reported that its preliminary assets under management (AUM) reached approximately $254.3 billion as of December 31, 2025.
nLIGHT (NASDAQ:LASR), a prominent manufacturer of high-power semiconductor and fiber lasers, announced preliminary fourth-quarter results for 2025 that exceeded its previous financial targets.
Delta Air Lines (NYSE:DAL) reported robust financial results for the fourth quarter and full year 2025, overcoming a year of fluctuating travel demand to deliver record cash flow and solid profitability.
Black Rifle Coffee Company (NYSE:BRCC) confirmed today that it expects to meet its previously issued financial targets for the 2025 fiscal year, despite a minor gross margin compression caused by a product formulation change.
Kestra Medical Technologies (NASDAQ:KMTS) has announced a strategic collaboration and exclusive co-development agreement with Biobeat Technologies to integrate advanced hemodynamic monitoring into its cardiac recovery platform.
Unity Bancorp (NASDAQ:UNTY), the parent company of Unity Bank, reported a record-breaking fiscal year 2025, characterized by robust loan growth and industry-leading profitability metrics.
